Overview

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
A treatment protocol that enables patients to have continued access to IPI-926.
Phase:
N/A
Details
Lead Sponsor:
Infinity Pharmaceuticals, Inc.
Treatments:
Veratrum Alkaloids